Participate in a Study

Clinical Trials

Participation in clinical trials and research is the only way we can hope to find cures for diseases such as Alzheimer's disease, and promote normal healthy brain and body aging for all!

Alzheimer's Disease Prevention and Treatment Clinical Trials

We have a variety of studies for individuals with and without memory loss. To discuss how you can participate please contact Shani Bardach, Clinical Trials and Outreach Coordinator, at shbardach@uky.edu or (859) 323-1331.
Steps to get involved in Clinical Trials:
1) Call or email Shani Bardach at (859) 323-1331 or shbardach@uky.edu
2) We'll ask you some questions to determine the study that would be the best fit for you
3) We will mail you study materials and put you in touch with the study coordinator
4) We'll give you a call to schedule a time to come in for a visit

AWARE

The purpose of the AWARE study is to test whether a new drug called ABBV-8E12 is safe and if it can slow down Alzheimer’s disease when recognized very early. Participation in this research study will involve 30 visits over the course of 27 months (https://www.theawarestudy.com/). Participants will receive either a low, medium, or high dose of the medication or a placebo through an IV once a month. You may be eligible to participate if you are ages 55-85 and have a diagnosis of mild cognitive impairment or mild Alzheimer’s disease, are in good general health, and are able to have an MRI scan. To learn more about participating, please contact Molly Harper, AWARE study coordinator, molly.harper@uky.edu, 859-323-2978. Click here to download the study flyer.

EARLY

The purpose of the EARLY study is to evaluate whether a new drug is beneficial for participants at risk for developing Alzheimer’s disease. Participants will either receive a low dose of the study medication, a high dose of the study medication, or a placebo. The EARLY study lasts 5 years (https://www.earlytrial.com/). You may be eligible to participate if you are 60-85 years old, have normal cognition, and are able to have an MRI scan. To learn more about participating, please contact Barbara Martin, EARLY study coordinator, bipatt@email.uky.edu, 859-323-0494. Click here to download the study flyer.

GENERATIONS

The purpose of the Generations study is to evaluate whether the study treatment (CAD106) is safe and has beneficial effects in people with normal cognition who may be at elevated risk for the onset of clinical symptoms of Alzheimer’s disease due to their age and genetic status. Participants will either receive the investigational medication or a placebo. The medication is an injection, received at the start of study, weeks 7, 13, and then every 13 weeks thereafter, until 6 months before completion of the study. Duration of the study will be between 5-8 years (http://www.generationstudy.com/how_will_the_generation_study_work.php). You may be eligible to participate if you are age 60-75, able to have an MRI scan, are in good general health, and have two copies of the APOE4 gene. To learn more about participating, please contact Carey Kebodeaux, Generations Study Coordinator, cakebodeaux@uky.edu, 859-323-3104. Click here to download the study flyer.

SUVN

The purpose of the SUVN study is to see if a new drug called SUVN 502 has an effect in improving symptoms of Alzheimer’s disease, to see if it is safe, to see how well it is tolerated, and to measure the levels of SUVN 502 in the blood. Participation in this research study involves 6 visits over 30 weeks (http://alztrials.us/). Participants will receive either a low dose or high dose of the medication or a placebo. You may be eligible to participate if you are ages 50-85, have been diagnosed with Alzheimer’s disease at least one year ago, and care currently taking a stable dose of Donepezil/Aricept and Memantine/Namenda or Namzaric. To learn more about participating, please contact Kendra Bates, SUVN Study Coordinator, Kendra.bates@uky.edu, (859) 257-5562. Click here to download the study flyer.

Ongoing Studies Closed for Enrollment

ALPHA STUDY

The purpose of the ALPHA study is to evaluate whether the use of a yeast-selenium supplement (AT-001) is safe and whether it may help improve brain health in individuals who do not have dementia. Participants will receive either the study drug or placebo for one year. Participants will have five visits over the course of 13-14 months. You may be eligible to participate if you are age 65 or older, do not have dementia, are in good general health, and are able to have an MRI scan. To learn more about participating, please contact Jane Garton, ALPHA study coordinator, jane.garton@uky.edu, 859-323-2499.Click here to download the study flyer.

A4: Anti-Amyloid for Asymptomatic Alzheimer’s

The purpose of the A4 study is to evaluate the study treatment (solanezumab) for people with normal cognition who are at risk for developing Alzheimer’s disease on the basis of having biomarker evidence of amyloid. This study will test the hypothesis that decreasing amyloid burden during the preclinical stages of Alzheimer’s disease will delay future cognitive decline. Participants will receive treatment for 3 years with either the anti-amyloid infusion drug or the placebo. (http://www.a4study.org/). You may be eligible to participate if: You are 65-85 years old, have normal cognition, and are able to have an MRI scan. Click here to download the study flyer.

AXOVANT

The purpose of the Axovant study is to evaluate a new medication (RVT-101)’s ability to improve cognition and activities of daily living. Participating in this study involves 13 visits over 8 months. Participants will either receive the study drug or a placebo. You may be eligible to participate if: you are 50-85 years old and have Dementia with Lewy Bodies (http://axovant.com/clinical-trials/headway-dlb/). Click here to download the study flyer.

BAN-2401

The purpose of the BAN-2401 study is to examine whether an anti-amyloid medication may slow or stop the progression of Alzheimer’s disease in people with mild cognitive impairment and mild Alzheimer’s disease. We hope to find out whether the study medication can reduce the amount of amyloid in the brain that might be causing the memory and thinking problems. Participation in this research study lasts 2 years and involves bi-weekly infusions of the study drug or a placebo (https://www.nia.nih.gov/alzheimers/clinical-trials/ban2401-early-alzheimers-disease). You may be eligible to participate if: you are 50 years of age or older and have either mild cognitive impairment or mild Alzheimer’s disease. Click here to download the study flyer. (pdf)

Gemfibrozil

The purpose of the Gemfibrozil study is to evaluate whether the use of gemfibrozil, a commonly used FDA-approved cholesterol lowering medication, can alter microRNA levels that may play a role in the development of Alzheimer’s disease. Participation in this research study involves nine visits to the clinic over approximately one year. You may be eligible to participate if: you are between 65 and 90 years of age, have either a diagnosis of mild cognitive impairment or have normal memory and thinking, are in good general health, and are not currently taking a cholesterol lowering mediation.Click here to download the study flyer (pdf)

The purpose of NOBLE is to evaluate an investigational drug for patients with mild to moderate Alzheimer’s disease. Participants will receive the study drug or placebo. The study drug may work by protecting brain cells which would result in improved memory, but this has not been proven yet. This study is to find out if the medication is both safe and effective for the target population. Participation in this research study involves 14 visits over 62 weeks. (http://www.adcs.org/studies/Noble.aspx). You may be eligible to participate if: You are 55-85 years of age, have a current diagnosis of Alzheimer’s disease, and are currently taking Aricept (donepezil) or Exelon (rivastigmine). Click here to download the study flyer (pdf)

Mild Cognitive Impairment-Cerebrovascular Disease (MCI-CVD)

The purpose of the MCI-CVD is to evaluate a heart health intervention for early detection and prevention of mild cognitive impairment due to cerebrovascular disease. Participants in this study will have their vascular risks monitored every 6 months and receive medical management and health education programs through the heart health intervention. Participation in this study will last three years. You may be eligible to participate if you are ages 55 of older, have memory complaints, and have one or more vascular risk factors (e.g. hypertension, high cholesterol, diabetes, stroke, obesity, tobacco use). Click here to download the study flyer.

STEADFAST

The purpose of the STEADFAST study is to evaluate a new investigational medication, azeliragon (TTP488), as an addition to many of the commonly prescribed medications for patients with mild Alzheimer’s disease. Participation in this research study involves 9 visits over 23 months (http://www.steadfastalzheimers.com/). You may be eligible to participate if you are at least 50 years of age, have been diagnosed with mild Alzheimer’s disease, and have been taking one or more of the following medications for at least 3 months: Namenda (Memantine), Razadyne (Galantamine), Aricept (donepezil), or Exelon (Rivastigmine). Click here to download the study flyer.